← Back to catalogue

Tennant & Kelman Type II Transducer, Ultrasonic, Obstetric

FDA PMA

Class II (US FDA PMA)

PMA P800016

by Bausch & Lomb, Inc.

Identity

Trade Name
TENNANT(TM) & KELMAN(TM) TYPE II FDA PMA
Generic Name
Transducer, ultrasonic, obstetric FDA PMA

Identifiers

PMA Number
P800016 FDA PMA
FDA Product Code
HGL FDA PMA

Classification

Device Class
Class II FDA PMA
Legislation / Framework
21 CFR Part 884.2960 FDA PMA
Regulation Number
884.2960 FDA PMA
Advisory Committee
Ophthalmic FDA PMA
FDA Decision
APPR Approved FDA PMA
PMA Supplement
S007 FDA PMA

This device is an ultrasonic transducer for obstetric use, classified as a Class II medical device under FDA regulations. It is designed for imaging fetal development and maternal anatomy during pregnancy, enabling real-time visualization of the fetus and surrounding tissues through high-frequency sound waves. The transducer operates within the parameters of obstetric ultrasound technology, adhering to safety and performance standards for diagnostic imaging.

The Tennant & Kelman Type II is supplied as a reusable device, intended for use in clinical settings such as obstetrics and gynecology departments. It is regulated under FDA PMA (Premarket Approval) and falls under the product code HGL, with a primary application in obstetric ultrasound examinations. Storage and handling must comply with manufacturer guidelines to ensure proper functionality and sterility before each use, though specific sterility claims are not stated in the data.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Active

FDA_PMA

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Bausch & Lomb, Inc.

Sources (1)

  • FDA PMA P800016 24 fields · synced Sep 18, 2026